A nurse is teaching a client who has a new prescription for gemfibrozil. Which of the following findings should the nurse instruct the client to report as an adverse effect of the medication?

Simvastatin is an HMG-CoA reductase inhibitorused to treat dyslipidemia by reducing hepatic cholesterol synthesis. While effective for cardiovascular prophylaxis, it carries risks of hepatotoxicityand myopathy. Clinical monitoring focuses on liver function tests and markers of muscle integrity to detect early signs of statin-inducedorgan injury.

Rationale:

A.Decreased creatine kinase (CK) is not a finding of clinical concern; however, increased CK would be highly significant. Elevated CK levels indicate muscle breakdown or rhabdomyolysis, which is a rare but severe side effect of statin therapy. A low or normal CK level suggests that the medication is not currently causing significant damage to the client's skeletal muscle tissue.

B.Increased alkaline phosphatase is a marker of potential liver injury or biliary obstruction and must be reported to the provider immediately. Since simvastatin is processed by the liver, it can cause asymptomatic elevations in liver enzymes or, in rare cases, drug-induced hepatitis. The nurse must monitor for jaundice and upper quadrant pain when these laboratory values are elevated.

C.Increased HDL is a positive therapeutic outcome of simvastatin therapy and does not need to be reported as an adverse finding. High-density lipoprotein is the "good" cholesterol that aids in the transport of cholesterol away from the arteries. An increase in this value indicates that the medication and lifestyle changes are successfully reducing the client's overall cardiovascular risk profile.

D.Decreased HbA1c is generally a favorable finding, as it indicates improved long-term glucose control. Statins have actually been associated with a slight increase in HbA1c and blood glucose levels in some patients, potentially increasing the risk of diabetes. Therefore, a decrease would not be considered a medication-related adverse effect that requires urgent notification to the healthcare provider.

Enoxaparin is a low-molecular-weight heparin(LMWH) that exerts anticoagulant effects by accelerating the activity of antithrombin III, primarily inhibiting factor Xa. It is used for the prophylaxis and treatment of deep vein thrombosisand pulmonary embolism. Unlike unfractionated heparin, it has a more predictable pharmacological profile and typically does not require routine laboratory monitoring of clotting times.

Rationale:

A.Diarrhea is not a common or expected side effect of enoxaparin therapy, as the drug does not significantly affect the gastrointestinal microbiome. The most concerning side effects are related to bleeding or heparin-induced thrombocytopenia. If a patient experiences diarrhea, the nurse should investigate other causes such as dietary changes, infections, or different medications.

B.Monitoring the skin for bruising is a vital safety instruction because enoxaparin increases the risk of bleeding and hemorrhage. Bruising or ecchymosis can indicate that the medication is excessively thinning the blood or that the patient has experienced minor trauma. Early detection of bleeding allows for prompt medical intervention to adjust the dosage or manage complications.

C.Enoxaparin must be injected into the subcutaneous tissue, typically in the abdomen, and should never be injected into a muscle. Intramuscular injection of anticoagulants can cause the formation of painful and dangerous hematomas due to the high vascularity of muscle tissue. The nurse must ensure the client understands the correct technique for deep subcutaneous administration.

D.Weekly INR checks are required for patients taking warfarin, but they are not necessary for those on enoxaparin. Enoxaparin provides a very stable and predictable anticoagulant response that does not require the frequent dose adjustments associated with Vitamin K antagonists. This lack of required blood work is one of the primary benefits of LMWH therapy.